Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström’s Macroglobulinemia (iNNOVATE)

M. Lia Palomba,Meletios A. Dimopoulos,Alessandra Tedeschi,Judith Trotman,Ramón García-Sanz,David MacDonald,Veronique Leblond,Beatrice Mahe,Charles Herbaux,Constantine Tam,Jeffrey V. Matous,Chaim Shustik,Efstathios Kastritis,Steven P. Treon,Jianling Li,Zeena Salman,Thorsten Graef,Christian Buske

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2018）

引用 0|浏览33

暂无评分

摘要

Ibrutinib, a once-daily inhibitor of Bruton’s Tyrosine Kinase, is approved in the US and EU for the treatment of Waldenström’s macroglobulinemia (WM).

查看译文

关键词

Waldenstrom's macroglobulinemia,ibrutinib,combination therapy,rituximab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要